Vaccinex is a biotechnology business based in the US. Vaccinex shares (VCNX) are listed on the PINK and all prices are listed in US Dollars. Its last market close was $1.00 – an increase of 2.04% over the previous week. Vaccinex employs 23 staff and has a trailing 12-month revenue of around $601,000.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $1.00 |
|---|---|
| 52-week range | $0.25 - $8.90 |
| 50-day moving average | $0.82 |
| 200-day moving average | $2.76 |
| Wall St. target price | $7.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-8.88 |
Historical closes compared with the close of $0.67 from 2025-05-02
| 1 week (2025-04-28) | 0.67 |
|---|---|
| 1 month (2025-04-04) | 11.67% |
| 3 months (2025-02-06) | -33.00% |
| 6 months (2024-11-06) | -79.57% |
| 1 year (2024-05-06) | -88.55% |
|---|---|
| 2 years (2023-05-05) | -99.09% |
| 3 years (2022-05-05) | 279.3 |
| 5 years (2020-05-06) | 766.5 |
| Revenue TTM | $601,000 |
|---|---|
| Gross profit TTM | $-11,944,000 |
| Return on assets TTM | -376.08% |
| Return on equity TTM | -759.09% |
| Profit margin | 0% |
| Book value | $-1.55 |
| Market Capitalization | $2.7 million |
TTM: trailing 12 months
We're not expecting Vaccinex to pay a dividend over the next 12 months.
Vaccinex's shares were split on a 1:14 basis on 19 February 2024 . So if you had owned 14 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Vaccinex shares – just the quantity. However, indirectly, the new 1300% higher share price could have impacted the market appetite for Vaccinex shares which in turn could have impacted Vaccinex's share price.
Over the last 12 months, Vaccinex's shares have ranged in value from as little as $0.25 up to $8.9. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (PINK average) beta is 1, while Vaccinex's is 1.353. This would suggest that Vaccinex's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Vaccinex, Inc. , a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for treatment of Alzheimer's disease and has completed phase 2 study for treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab completed phase 2 study for melanoma, and trastuzumab and DC vaccine in phase 2 study for breast cancer. The company has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. It has collaborations with Merck Sharp & Dohme; Ares Trading S. A.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Some of the best stock trading apps for beginners include SoFi, Robinhood, Public, Stash, Opto and more. Compare your options here.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 7 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
Fidelity is best for its extensive tools and resources, while Robinhood is a popular choice for its simple, easy-to-use platform.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .